Wu Jing-Yu, Song Qing-Yu, Huang Chang-Zhi, Shao Yu, Wang Zhen-Ling, Zhang Hong-Qiang, Fu Zan
The General Surgery Laboratory, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
The General Surgery Laboratory, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Genet. 2022 Jul 22;13:952836. doi: 10.3389/fgene.2022.952836. eCollection 2022.
7-Methylguanosine(m7G) contributes greatly to its pathogenesis and progression in colorectal cancer. We proposed building a prognostic model of m7G-related LncRNAs. Our prognostic model was used to identify differences between hot and cold tumors. The study included 647 colorectal cancer patients (51 cancer-free patients and 647 cancer patients) from The Cancer Genome Atlas (TCGA). We identified m7G-related prognostic lncRNAs by employing the univariate Cox regression method. Assessments were conducted using univariate Cox regression, multivariate Cox regression, receiver operating characteristics (ROC), nomogram, calibration curves, and Kaplan-Meier analysis. All of these procedures were used with the aim of confirming the validity and stability of the model. Besides these two analyses, we also conducted half-maximal inhibitory concentration (IC50), immune analysis, principal component analysis (PCA), and gene set enrichment analysis (GSEA). The entire set of m7G-related (lncRNAs) with respect to cold and hot tumors has been divided into two clusters for further discussion of immunotherapy. The risk model was constructed with 17 m7G-related lncRNAs. A good correlation was found between the calibration plots and the prognosis prediction in the model. By assessing IC50 in a significant way across risk groups, systemic treatment can be guided. By using clusters, it may be possible to distinguish hot and cold tumors effectively and to aid in specific therapeutic interventions. Cluster 1 was identified as having the highest response to immunotherapy drugs and thus was identified as the hot tumor. This study shows that 17 m7G-related lncRNA can be used in clinical settings to predict prognosis and use them to determine whether a tumor is cold or hot in colorectal cancer and improve the individualization of treatment.
7-甲基鸟苷（m7G）在结直肠癌的发病机制和进展中起着重要作用。我们提出构建一个与m7G相关的长链非编码RNA（lncRNA）的预后模型。我们的预后模型用于识别冷热肿瘤之间的差异。该研究纳入了来自癌症基因组图谱（TCGA）的647例结直肠癌患者（51例无癌患者和647例癌症患者）。我们采用单因素Cox回归方法识别与m7G相关的预后lncRNA。使用单因素Cox回归、多因素Cox回归、受试者工作特征曲线（ROC）、列线图、校准曲线和Kaplan-Meier分析进行评估。所有这些程序旨在确认模型的有效性和稳定性。除了这两项分析外，我们还进行了半数最大抑制浓度（IC50）、免疫分析、主成分分析（PCA）和基因集富集分析（GSEA）。关于冷热肿瘤的整个m7G相关（lncRNA）集合已分为两个簇，以进一步讨论免疫治疗。风险模型由17个与m7G相关的lncRNA构建。在校准图和模型中的预后预测之间发现了良好的相关性。通过以显著方式评估不同风险组的IC50，可以指导全身治疗。通过使用簇，可能有效地区分冷热肿瘤并有助于进行特定的治疗干预。簇1被确定为对免疫治疗药物反应最高，因此被确定为热肿瘤。这项研究表明，17个与m7G相关的lncRNA可用于临床环境中预测预后，并用于确定结直肠癌肿瘤是冷还是热，从而改善治疗的个体化。
